8-K: Profound Medical Regains Canadian TULSA-PRO Rights

Profound Medical Corp. has regained exclusive distribution rights for its TULSA-PRO system in Canada from Knight Therapeutics Inc.

Summary

• Profound Medical Corp. regained exclusive distribution rights for TULSA-PRO in Canada from Knight Therapeutics Inc.
• The TULSA-PRO system is an AI-powered, MRI-guided, incision-free therapy for ablating diseased prostate tissue, including prostate cancer and/or benign prostatic hyperplasia (BPH).
• Profound made a one-time cash payment of CDN$90,000 (US$64,000) to Knight Therapeutics Inc. for the rights.
• Profound will pay a 5% royalty on Canadian Net Sales for 15 years to Knight Therapeutics Inc.
• Toronto's Sunnybrook Health Sciences Centre, the original innovator of the TULSA-PRO technology, is currently the only Canadian site offering the procedure and has performed over 100 TULSA Procedures.
• Profound plans to use results from the Level I prostate cancer CAPTAIN trial, comparing the TULSA Procedure head-to-head with robotic radical prostatectomy (expected 2026+), to support applications for Canadian Provincial Health Insurance coverage.
• The company also sees an opportunity to grow its TULSA-PRO business in Canada via additional sites using a concierge service model on an interim basis.
• TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Sentiment

Score: 8

Explanation: The regaining of distribution rights is a strong strategic positive, enabling direct control and integrated commercial efforts in Canada. While there's an immediate cash outlay and ongoing royalty, the long-term growth potential in Canada, especially with anticipated positive trial results and subsequent insurance coverage, is significant. The TULSA-PRO technology is innovative and has demonstrated initial success at Sunnybrook, positioning the company well for future expansion.

Positives

• Regained exclusive distribution rights for TULSA-PRO in Canada, allowing direct control over commercialization and market strategy.
• Can now leverage Profound's North American integrated commercial and clinical teams for the TULSA-PRO launch in Canada, which is expected to be more effective for a complex medical device.
• The existing Canadian site, Sunnybrook Health Sciences Centre, has successfully performed over 100 TULSA Procedures, demonstrating established clinical adoption.
• Significant potential for market expansion and growth in Canada if provincial health insurance coverage is approved, supported by future CAPTAIN trial results (expected 2026+).
• Opportunity to expand the TULSA-PRO business in Canada through additional sites using a concierge service model on an interim basis.
• The TULSA Procedure offers a major advancement in prostate care, being incisionand radiation-free, with no hospital stay required and quick patient recovery.
• TULSA-PRO is highlighted as the only AI-powered, MRI-guided robotic system for prostate treatment, indicating a unique competitive advantage.

Negatives

• Incurred a one-time cash payment of CDN$90,000 (US$64,000) to Knight Therapeutics Inc. for regaining the distribution rights.
• Will pay an ongoing 5% royalty on Canadian Net Sales for 15 years to Knight Therapeutics Inc., impacting future revenue margins in Canada.
• Currently, only one Canadian site offers the TULSA Procedure, indicating a nascent market that requires significant development.
• Securing provincial health insurance coverage is not guaranteed and is contingent on future trial results and successful applications, introducing a degree of uncertainty.

Risks

• Risks inherent in the medical device industry, including product development, manufacturing, and market acceptance.
• Uncertainty regarding obtaining and maintaining necessary regulatory approvals for products in various jurisdictions.
• Challenges in securing adequate reimbursement for procedures from healthcare payers and insurance authorities.
• Impact of broader economic factors on consumer spending, healthcare budgets, and market demand.
• Volatility and general conditions of the equity markets affecting company valuation and access to capital.
• Risks associated with business growth, including scaling operations, managing supply chains, and maintaining quality control.
• Intense competition from existing and new market entrants offering alternative prostate treatment solutions.
• Forward-looking statements and financial projections may not align with actual results due to market factors and operational execution.
• Actual financial results, including revenue, operating expenses, and cash usage, may deviate from management's expected ranges.

Future Outlook

The company anticipates leveraging the results of the Level I prostate cancer CAPTAIN trial, expected to be published in 2026 and beyond, to support applications for provincial health insurance coverage in Canada. This coverage is viewed as a significant opportunity to expand the TULSA Procedure at Sunnybrook Health Sciences Centre and other hospitals across Canada. In the interim, Profound plans to grow its Canadian TULSA-PRO business through additional sites utilizing a concierge service model. The company is also in the early stages of exploring additional potential treatment markets for its Sonalleve platform, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Management Comments

• "Knight has been a strong supporter of Profound and its groundbreaking TULSA technology for the treatment of prostate disease, including cancer and/or BPH." Samira Sakhia, President and CEO of Knight Therapeutics Inc.
• "Knight's strategy across Canada and Latin America is to commercialize innovative pharmaceutical products. The launch of TULSA-PRO in Canada, a complex medical device technology, will be served best by Profound's North American integrated commercial and clinical teams." Samira Sakhia, President and CEO of Knight Therapeutics Inc.
• "Toronto's renowned Sunnybrook Health Sciences Centre, the original innovator of the TULSA-PRO technology, has already performed more than 100 TULSA Procedures." Arun Menawat, CEO and Chairman of Profound Medical Corp.
• "Moving forward, as the results of the Level I prostate cancer CAPTAIN trial comparing the TULSA Procedure head-to-head with robotic radical prostatectomy are published in 2026 and beyond, we plan to use them to support our applications to the appropriate Canadian Provincial Health Insurance authorities for coverage." Arun Menawat, CEO and Chairman of Profound Medical Corp.
• "If coverage is approved, we see an even larger opportunity for the TULSA Procedure at Sunnybrook and, indeed, at hospitals across Canada." Arun Menawat, CEO and Chairman of Profound Medical Corp.
• "In the meantime, we also see an opportunity to continue to grow our TULSA-PRO business in Canada via additional sites using the concierge service model on an interim basis." Arun Menawat, CEO and Chairman of Profound Medical Corp.

Industry Context

This strategic move positions Profound Medical to directly capitalize on the increasing demand for minimally invasive and precise prostate treatment options. The TULSA Procedure, with its AI-powered, MRI-guided, incision-free approach, aligns with broader industry trends favoring advanced medical devices that enhance patient outcomes, reduce recovery times, and enable personalized treatment. Regaining direct control over Canadian distribution allows Profound to integrate its commercial strategy across North America, potentially accelerating market penetration and adoption in a key developed market for medical technology.

Comparison to Industry Standards

• The CAPTAIN trial is a Level I study designed to compare the TULSA Procedure head-to-head with robotic radical prostatectomy, a widely accepted surgical treatment for prostate cancer, aiming to demonstrate superior or equivalent outcomes.
• The TULSA Procedure is presented as a significant advancement over traditional treatments like surgery and radiation, emphasizing its incisionand radiation-free nature, single-session treatment, lack of hospital stay, and quick recovery, while aiming to preserve urinary continence and sexual function.
• TULSA-PRO is highlighted as the only AI-powered, MRI-guided robotic system for prostate treatment, suggesting a unique technological position and differentiation from other prostate treatment modalities in the market.

Stakeholder Impact

• Shareholders: Potential for increased revenue, market share, and long-term value creation in Canada, offset by an initial cash outflow and ongoing royalty payments.
• Patients: Increased access to an innovative, incision-free prostate treatment (TULSA Procedure) in Canada, potentially offering improved outcomes and faster recovery compared to traditional methods.
• Employees: Potential for growth in Profound's Canadian operations, possibly leading to increased hiring for commercial and clinical teams.
• Knight Therapeutics Inc.: Receives a one-time cash payment and a 5% royalty on future Canadian net sales for 15 years, while exiting a complex medical device distribution business to focus on pharmaceutical products.

Next Steps

• Publication of Level I prostate cancer CAPTAIN trial results (expected in 2026 and beyond).
• Applications to appropriate Canadian Provincial Health Insurance authorities for coverage based on CAPTAIN trial results.
• Expansion of the TULSA-PRO business in Canada via additional sites using the concierge service model on an interim basis.
• Continued deployment of Profound's direct sales team in North America.
• Partnering with select strategic distribution partners to support business potential and customer base in other parts of the world.
• Early-stage exploration of additional potential treatment markets for Sonalleve, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Key Dates

Recommendation

The regaining of exclusive distribution rights for TULSA-PRO in Canada is a strategically sound move, allowing Profound Medical to directly control and integrate its commercial efforts in a key market. This direct control, combined with the proven success at Sunnybrook Health Sciences Centre and the anticipated positive impact of the CAPTAIN trial results on provincial health coverage, positions the company for significant long-term growth. While there's an immediate cash outlay and ongoing royalty, the potential for increased market penetration and revenue generation from a highly innovative and differentiated technology outweighs these costs. The TULSA-PRO system addresses a large market (prostate cancer and BPH) with a superior, minimally invasive solution, making this a strong positive catalyst for future performance.

Keywords

TULSA-PRO, Profound Medical, prostate cancer, BPH, benign prostatic hyperplasia, medical device, MRI-guided, ultrasound, Canada, distribution rights, Knight Therapeutics, AI-powered, robotic surgery, prostate treatment, healthcare, medical technology, CAPTAIN trial